Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg weight-adjusted daily) showed no clear difference in total number of oral ulcers compared with placebo (moderate certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics from 0‐2 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Vomiting, retching, or antiemetics 0‐12 hours · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
Anaphylactoid symptoms · people with paracetamol (acetaminophen) overdose
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Improvement in oral ulcer score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg three times daily for 6 months) showed no clear difference in improvement in oral ulcer score compared with placebo; GRADE not reported.
1 finding from 1 review
Volatile sulphur compounds (VSC), halimeter · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Awareness of prolapse · vaginal prolapse
Transvaginal permanent mesh probably leads to lower awareness of prolapse (0.5 to 7 years) compared with native tissue repair (moderate certainty).
1 finding from 1 review
Need for repeat surgery · vaginal prolapse
Transvaginal permanent mesh may leads to higher repeat surgery (0.5 to 7 years) compared with native tissue repair (low certainty).
1 finding from 1 review
Length of hospital stay · treating kidney stones
1 finding from 1 review
Length of hospital stay · treating kidney stones
1 finding from 1 review
Neutropenia · people with non‐transfusion‐dependent β‐thalassaemia
It is very uncertain whether one dose or dose regimen of a foetal haemoglobin inducer changes neutropenia (WBC < 1 × 103/μL, ANC < 0.5 × 103/μL) compared with another dose or dose regimen of the same foetal haemoglobin inducer (very low certainty).
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (36 studies, 6263 participants) in the analysis Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (36 studies, 6263 participants) in the analysis Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
High‐dose atropine (≥ 0.5%) · children with progressive myopia (21 studies, 4169 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review